[16] GLP-1 endogenous in humans [16] glucagon endogenous in humans [16] oxyntomodulin amycretin/ zenagamtide UBT251 exendin-4 [16] [17] exenatide lixisenatide [16] albiglutide beinaglutide dulaglutide efpeglenatide langlenatide liraglutide [16] polyethylene glycol/PEG- loxenatide semaglutide taspoglutide ecnoglutide utreglutide glepaglutide apraglutide maridebart cafraglutide tirzepatide pegapamodutide mazdutide survodutide bamadutide pemvidutide cotadutide retatrutide Lithium chloride Cinchonine grutalumab dapiglutide DA1726 GX-G6 GZR18 HRS9531/ KAI-9531/ Ribupatide PB718 RAY1225 VCT220 VK2735 BLX7006 supaglutide/ efsubaglutide ASC30 HRS7535 Danuglipron Aleniglipron Lotiglipron Orforglipron (non peptide partial agonist) [18] Conveglipron Elecoglipron/ AZD 5004/ ECC 5004 CT-996 CT-388/ Enicepatide CT-868 HEC88473 HS-10535 UBT251 efinopegdutide efocipegtrutide Berobenatide NNC9204-1706 TG103 YP05002/YP-05002 Positive Negative Clinical significance [edit] GLP-1 receptor agonists are a class of medications that mimic the actions of the endogenous incretin hormone GLP-1, and are used in type 2 diabetes and obesity
Managing type 2 diabetes involves regular lab tests and ongoing physical care, necessitating in-person evaluations
If youre interested in GLP-1 weight loss treatments, Pure Med Spa Chicago is here to help
A case of trigeminal malignant melanotic nerve sheath tumor in the wide Spectrum of melanotic and nerve sheath tumors
The final set of studies includes multiple randomized, double-blind, placebo- or active-controlled clinical trials (e.g., Bode 2010, Ji 2021, Husain 2019, Gerstein 2019, Kelly 2020, etc.), as well as several large-scale retrospective or prospective cohort studies from regions including Europe, Taiwan, the United States, and Nordic countries (e.g., Kornelius 2024, Chang 2025, Tagliapietra 2024, Ueda/Wadden 2024, and multinational database analyses)
